Two-Step Remission Induction With Risk-Oriented Consolidation (High-Risk: Allogeneic Stem Cell Transplant; Standard-Risk: Multicycle High-Dose Cytarabine With Autologous Blood Stem Cell Support) for Adult Acute Myelogenous Leukemia
Two-Step Remission Induction With Risk-Oriented Consolidation (High-Risk: Allogeneic Stem Cell Transplant; Standard-Risk: Multicycle High-Dose Cytarabine With Autologous Blood Stem Cell Support) for Adult Acute Myelogenous Leukemia is a PHASE2 clinical asset sponsored by Northern Italy Leukemia Group in Acute Myelogenous Leukemia. SEO and diligence focus: Two-step remission induction and risk-oriented consolidation, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Acute Myelogenous Leukemia
Modality: behavioral intervention
Target: Two-step remission induction and risk-oriented consolidation
Sponsor: Northern Italy Leukemia Group
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Two-step remission induction and risk-oriented consolidation
View original source fields
Condition raw: Acute Myelogenous Leukemia
Condition normalized: Acute Myelogenous Leukemia
Modality raw: behavioral intervention
Modality normalized: behavioral intervention
Target raw: Two-step remission induction and risk-oriented consolidation
Target normalized: Two-step remission induction and risk-oriented consolidation